Risdiplam (Evrysdi™). HTA ID: 21006
Risdiplam (Evrysdi™) is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 15/03/2021 |
| Rapid review completed | 29/03/2021 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of risdiplam compared with the current standard of care. |